Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.

Continue » The leader in diabetes and obesity Despite Lilly's huge success in treating diabetes and obesity, it's not the ...

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, ...

Learn how and where to inject Zepbound and where to get additional help. Plus, get tips for injecting the drug at home and ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly’s orforglipron pill, licensed from Chugai Pharmaceutical, could reshape the booming weight-loss drug market, early ...

Eli Lilly's new oral weight loss pill, orforglipron, shows promise in Phase 3 trials, offering a convenient alternative to ...

A co-defendant in a deadly rock-throwing attack in Colorado took the stand Thursday to testify against his friend. The future ...

If approved for wide release, the pill, orforglipron, could shake up the booming GLP-1 market by offering an option that's easier to make and store than the injections that are currently available.

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Eli Lilly stocks displayed a major rise after the announcement of a new oral weight-loss drug that has put pressure on its ...